Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12.
Interactions between the Fc segment of IgG and FcγRs on a variety of cells are likely to play an important role in the anti-HIV activity of Abs. Because the nature of the glycan structure on the Fc domain is a critical determinant of Fc-FcγR binding, proper Fc glycosylation may contribute to Ab-mediated protection. We have generated five different glycoforms of the broadly HIV-1-neutralizing mAb 2G12 in wild-type and glycoengineered plants and Chinese hamster ovary cells. Plant-derived 2G12 exhibited highly homogeneous glycosylation profiles with a single dominant N-glycan species. Using flow cytometry with FcγR-expressing cell lines, all 2G12 glycoforms demonstrated similar binding to FcγRI, FcγRIIa, and FcγRIIb. In contrast, two glycoforms derived from glycoengineered plants that lack plant-specific xylose and core α1,3-fucose, and instead carry human-like glycosylation with great uniformity, showed significantly enhanced binding to FcγRIIIa compared with Chinese hamster ovary or wild-type plant-derived 2G12. Using surface plasmon resonance, we show that binding of 2G12 to FcγRIIIa is markedly affected by core fucose, irrespective of its plant-specific α1,3 or mammalian-type α1,6 linkage. Consistent with this finding, 2G12 glycoforms lacking core fucose (and xylose) mediated higher antiviral activity against HIV-1 or simian immunodeficiency virus as measured by Ab-dependent cell-mediated virus inhibition. This is, to our knowledge, the first demonstration that specific alterations of Fc glycosylation can improve antiviral activity. Such alterations may result in better immunotherapeutic reagents. Moreover, biasing vaccine-induced immune responses toward optimal Fc glycosylation patterns could result in improved vaccine efficacy.
Division of Infectious Diseases, Department of Medicine, University of California, Irvine School of Medicine, Irvine, CA 92697, USA. dnfortha@uci.edu
Donald N
DN
Forthal
Johannes S
JS
Gach
Gary
G
Landucci
Jakub
J
Jez
Richard
R
Strasser
Renate
R
Kunert
Herta
H
Steinkellner
D016915:AIDS Vaccines / Q000276:immunology; D000818:Animals; D019380:Anti-HIV Agents / Q000378:metabolism / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology; D001666:Binding Sites, Antibody / Q000276:immunology; D000080908:Broadly Neutralizing Antibodies; D016466:CHO Cells; D002460:Cell Line; D006224:Cricetinae; D003412:Cricetulus; D006031:Glycosylation; D015483:HIV Antibodies; D015497:HIV-1 / Q000235:genetics / Q000254:growth & development / Q000276:immunology*; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000378:metabolism*; D016180:Lentivirus Infections / Q000276:immunology / Q000378:metabolism / Q000517:prevention & control; D009500:Neutralization Tests / Q000379:methods; D011485:Protein Binding / Q000276:immunology; D017452:Receptors, IgG / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000254:growth & development / Q000276:immunology; D014026:Nicotiana / Q000235:genetics / Q000276:immunology
C529157:2G12 monoclonal antibody; D016915:AIDS Vaccines; D019380:Anti-HIV Agents; D000911:Antibodies, Monoclonal; D000080908:Broadly Neutralizing Antibodies; C496124:FCGR3A protein, human; D015483:HIV Antibodies; D007141:Immunoglobulin Fc Fragments; D017452:Receptors, IgG